C12N 2795/00071
Demonstrated in vivo effect
C12N2795/00071 (Demonstrated in vivo effect) appears on 22 US grants and 33 published applications in this corpus.
Search patents in C12N- Granted patents
- 22
- Published applications
- 33
- Assignees
- 17
- Inventors
- 49
- Latest grant
- 16 Apr 2024
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 2003 | 0 | 1 |
| 2004 | 0 | 0 |
| 2005 | 1 | 1 |
| 2006 | 0 | 0 |
| 2007 | 0 | 0 |
| 2008 | 1 | 1 |
| 2009 | 0 | 0 |
| 2010 | 1 | 3 |
| 2011 | 2 | 0 |
| 2012 | 0 | 3 |
| 2013 | 3 | 2 |
| 2014 | 1 | 2 |
| 2015 | 2 | 1 |
| 2016 | 2 | 2 |
| 2017 | 1 | 2 |
| 2018 | 2 | 3 |
| 2019 | 0 | 1 |
| 2020 | 2 | 2 |
| 2021 | 1 | 1 |
| 2022 | 1 | 0 |
| 2023 | 1 | 1 |
| 2024 | 1 | 1 |
| 2025 | 0 | 4 |
| 2026 | 0 | 2 |
By publication year. 2026 runs to 8 Oct.
Recent patents
- Phage therapy of E coli infections16 Apr 2024US 11,957,724 B2Erytech Pharma
- Bacteriophage compositions comprising respiratory antibacterial phages and methods of use thereof13 Jun 2023US 11,672,839 B2Technechnophage, Investigacao E Desenvolvimento Em Biotecnologia, SA
- Virus-like particle with efficient epitope display15 Nov 2022US 11,497,800 B2University of Copenhagen
- Phage therapy of E coli infections16 Feb 2021US 10,918,680 B2Pherecydes Pharma
- Anti-tumor medicament based on adenovirus1 Dec 2020US 10,851,359 B2Medizinische Hochschule Hannover
- Bacteriophage27 Aug 2026US 2026/0250642 A1Arrowsmith Inc.
- Bacteriophages for the control of bacterial spot and bacterial speck disease6 Aug 2026US 2026/0223860 A1
- Bacteriophage having bacteriolysis activity on xanthomonas spp24 Apr 2025US 2025/0129129 A1Kaneka Corporation
- Bacteriophage having bacteriolysis activity on xanthomonas spp.20 Mar 2025US 2025/0089724 A1Kaneka Corporation
- Bacteriophage having bacteriolysis activity on xanthomonas spp20 Mar 2025US 2025/0089725 A1Kaneka Corporation
Most cited
By later US patents
- Compositions and methods for treatment of microbial infections20US 6,929,798 B2Immunology Laboratories, Inc. · 2005
- Compositions and methods for treatment of microbial infections16US 7,329,409 B2Immunology Laboratories, Inc. · 2008
- Compositions and methods for treatment of microbial infections12US 7,648,707 B2Immunology Laboratories, Inc. · 2010
- Compositions and methods for treatment of microbial infections10US 8,518,416 B2Immunology Laboratories, Inc. · 2013
- Compositions and methods for treatment of microbial infections8US 8,043,624 B2Immunology Laboratories, Inc. · 2011